These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37349237)

  • 21. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
    Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
    Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.
    Zhao Y; Wu L; Lu Q; Gao X; Zhu X; Yao X; Li L; Li W; Ding Y; Song Z; Liu L; Dang N; Zhang C; Liu X; Gu J; Wang J; Geng S; Liu Q; Guo Y; Dong L; Su H; Bai L; O'Malley JT; Luo J; Laws E; Mannent L; Ruddy M; Amin N; Bansal A; Ota T; Wang M; Zhang J
    Br J Dermatol; 2022 Apr; 186(4):633-641. PubMed ID: 34358343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 Jun; 182(6):e186-e209. PubMed ID: 32476149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator.
    Jiao Q; Qian Q; Liu C; Luo Y; Fang F; Wang M; Ji J; Qian H; Zhang X; Maurer M
    Br J Dermatol; 2020 Mar; 182(3):648-657. PubMed ID: 31090221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
    Siegfried EC; Bieber T; Simpson EL; Paller AS; Beck LA; Boguniewicz M; Schneider LC; Khokhar FA; Chen Z; Prescilla R; Mina-Osorio P; Bansal A
    Am J Clin Dermatol; 2021 Mar; 22(2):243-255. PubMed ID: 33655423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment.
    Simpson EL; Schlievert PM; Yoshida T; Lussier S; Boguniewicz M; Hata T; Fuxench Z; De Benedetto A; Ong PY; Ko J; Calatroni A; Rudman Spergel AK; Plaut M; Quataert SA; Kilgore SH; Peterson L; Gill AL; David G; Mosmann T; Gill SR; Leung DYM; Beck LA
    J Allergy Clin Immunol; 2023 Nov; 152(5):1179-1195. PubMed ID: 37315812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
    Boguniewicz M; Beck LA; Sher L; Guttman-Yassky E; Thaçi D; Blauvelt A; Worm M; Corren J; Soong W; Lio P; Rossi AB; Lu Y; Chao J; Eckert L; Gadkari A; Hultsch T; Ruddy M; Mannent LP; Graham NMH; Pirozzi G; Chen Z; Ardeleanu M
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1212-1223.e6. PubMed ID: 33453450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 36. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dupilumab Effects on Innate Lymphoid Cell and Helper T Cell Populations in Patients with Atopic Dermatitis.
    Imai Y; Kusakabe M; Nagai M; Yasuda K; Yamanishi K
    JID Innov; 2021 Mar; 1(1):100003. PubMed ID: 34909707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
    Silverberg JI; Lynde CW; Abuabara K; Patruno C; de Benedetto A; Zhang H; Thomas RB; Bégo-Le-Bagousse G; Khokhar FA; Vakil J; Marco AR; Levit NA
    Am J Clin Dermatol; 2023 May; 24(3):469-483. PubMed ID: 36808602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis.
    Nettis E; Patella V; Lombardo C; Detoraki A; Macchia L; Di Leo E; Carbonara M; Canonica GW; Bonzano L
    Allergy; 2020 Oct; 75(10):2653-2661. PubMed ID: 32424957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
    Paller AS; Wollenberg A; Siegfried E; Thaçi D; Cork MJ; Arkwright PD; Gooderham M; Sun X; O'Malley JT; Khokhar FA; Vakil J; Bansal A; Rosner K; Shumel B; Levit NA
    Paediatr Drugs; 2021 Sep; 23(5):515-527. PubMed ID: 34462864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.